183 related articles for article (PubMed ID: 22101738)
1. Cognitive efficacy of quetiapine in early-onset first-episode psychosis: a 12-week open label trial.
Urben S; Baumann P; Barcellona S; Hafil M; Preuss U; Peter-Favre C; Clarke S; Halfon O; Holzer L
Psychiatr Q; 2012 Sep; 83(3):311-24. PubMed ID: 22101738
[TBL] [Abstract][Full Text] [Related]
2. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
Keefe RS; Sweeney JA; Gu H; Hamer RM; Perkins DO; McEvoy JP; Lieberman JA
Am J Psychiatry; 2007 Jul; 164(7):1061-71. PubMed ID: 17606658
[TBL] [Abstract][Full Text] [Related]
3. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731
[TBL] [Abstract][Full Text] [Related]
4. Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis.
Robles O; Zabala A; Bombín I; Parellada M; Moreno D; Ruiz-Sancho A; Arango C
Schizophr Bull; 2011 Mar; 37(2):405-15. PubMed ID: 19706697
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders.
McConville BJ; Arvanitis LA; Thyrum PT; Yeh C; Wilkinson LA; Chaney RO; Foster KD; Sorter MT; Friedman LM; Brown KL; Heubi JE
J Clin Psychiatry; 2000 Apr; 61(4):252-60. PubMed ID: 10830145
[TBL] [Abstract][Full Text] [Related]
6. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol.
Purdon SE; Malla A; Labelle A; Lit W
J Psychiatry Neurosci; 2001 Mar; 26(2):137-49. PubMed ID: 11291531
[TBL] [Abstract][Full Text] [Related]
7. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
[TBL] [Abstract][Full Text] [Related]
8. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder.
Glick ID; Marder SR
J Clin Psychiatry; 2005 May; 66(5):638-41. PubMed ID: 15889952
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study.
Mullen J; Jibson MD; Sweitzer D
Clin Ther; 2001 Nov; 23(11):1839-54. PubMed ID: 11768836
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
Kinon BJ; Noordsy DL; Liu-Seifert H; Gulliver AH; Ascher-Svanum H; Kollack-Walker S
J Clin Psychopharmacol; 2006 Oct; 26(5):453-61. PubMed ID: 16974184
[TBL] [Abstract][Full Text] [Related]
11. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
[TBL] [Abstract][Full Text] [Related]
12. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.
Arvanitis LA; Miller BG
Biol Psychiatry; 1997 Aug; 42(4):233-46. PubMed ID: 9270900
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial.
Findling RL; McKenna K; Earley WR; Stankowski J; Pathak S
J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):327-42. PubMed ID: 23083020
[TBL] [Abstract][Full Text] [Related]
14. Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia.
Kasper S; Brecher M; Fitton L; Jones AM
Int Clin Psychopharmacol; 2004 Sep; 19(5):281-9. PubMed ID: 15289701
[TBL] [Abstract][Full Text] [Related]
15. Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis.
Good KP; Kiss I; Buiteman C; Woodley H; Rui Q; Whitehorn D; Kopala L
Br J Psychiatry Suppl; 2002 Sep; 43():s45-9. PubMed ID: 12271800
[TBL] [Abstract][Full Text] [Related]
16. Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia.
Goldberg TE; Burdick KE; McCormack J; Napolitano B; Patel RC; Sevy SM; Goldman R; Lencz T; Malhotra AK; Kane JM; Robinson DG
Schizophr Res; 2009 Feb; 107(2-3):262-6. PubMed ID: 19042105
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings.
Velligan DI; Prihoda TJ; Sui D; Ritch JL; Maples N; Miller AL
J Clin Psychiatry; 2003 May; 64(5):524-31. PubMed ID: 12755654
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial.
McConville B; Carrero L; Sweitzer D; Potter L; Chaney R; Foster K; Sorter M; Friedman L; Browne K
J Child Adolesc Psychopharmacol; 2003; 13(1):75-82. PubMed ID: 12804128
[TBL] [Abstract][Full Text] [Related]
19. Open-label study of the effect of combination quetiapine/lithium therapy on lithium pharmacokinetics and tolerability.
Potkin SG; Thyrum PT; Bera R; Carreon D; Alva G; Kalali AH; Yeh C
Clin Ther; 2002 Nov; 24(11):1809-23. PubMed ID: 12501876
[TBL] [Abstract][Full Text] [Related]
20. Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.
Galderisi S; Mucci A; Bitter I; Libiger J; Bucci P; Fleischhacker WW; Kahn RS;
Eur Neuropsychopharmacol; 2013 Mar; 23(3):196-204. PubMed ID: 22647933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
